

Transforming Patient Outcomes Through Life-changing Science and Innovation

Full Year 2024 Results and Recent Business Update
Earnings Call, February 13, 2025

Galápagos

Disclaimer

This presentation contains “forward looking statements”, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “vision,” “progress,” “believe,” “anticipate,” “plan,” “continue,” “forward,” “goal,” “should,” “expect,” “outlook,” “estimate,” “next,” “encouraging,” “aim,” and “will,” and “initiate” as well as any similar expressions. Forward looking statements contained herein include, but are not limited to, the anticipated separation of the company into two public companies, the corporate reorganization and related transactions, including the expected timeline of such transactions, anticipated changes to the management and board of directors of each company, the anticipated benefits and synergies of such transactions; the receipt of regulatory and shareholder approvals for such transactions; statements related to our plans and expectations regarding our collaboration with Gilead Sciences, Inc. (“Gilead”); the guidance from management regarding our financial results, including our expected operational use of cash following the anticipated transactions; statements related to our plans, expectations and strategy with respect to our product candidates and the potential benefits of our product candidates, including GLPG5101, and partnered programs, including uza-cel; statements regarding the expected timing, design and readouts of our ongoing and planned preclinical studies and clinical trials; statements regarding preliminary, interim and topline data from our preclinical and clinical studies, including expected timing for the release of data related to such studies, statements about our ability to advance product candidates into, and successfully complete, clinical trials; statements regarding the timing and likelihood of business development projects and external innovation; statements regarding our regulatory outlook, statements regarding our R&D plans, strategy and outlook; and any potential changes in such strategy, statements regarding our pipeline and complementary technology platforms facilitating future growth, and statements and expectations regarding the rollout of our products or product candidates (if approved). We caution the reader that forward-looking statements are based on our management’s current beliefs and expectations and are not guarantees of future performance. Forward-looking statements may involve any known and unknown risks, uncertainties and other factors which might cause our actual results, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such statements. Such risks include, but are not limited to, risks associated with the anticipated transactions, including the risk that regulatory and shareholder approvals required in connection with the transactions will not be received or obtained within the expected time frame or at all, the risk that the transactions and/or the necessary conditions to consummate the transactions will not be satisfied on a timely basis or at all, uncertainties regarding our ability to successfully separate Galapagos into two companies and realize the anticipated benefits from the separation within the expected time frame or at all, the two separate companies’ ability to succeed as stand-alone, publicly traded companies, the risk that costs of restructuring transactions and other costs incurred in connection with the transactions will exceed our estimates, the impact of the transactions on our businesses and the risk that the spin-off may be more difficult, time consuming or costly than expected; the risk that our beliefs, guidance, and expectations regarding our cash burn or runway, operational expenses or other financial metrics may be incorrect (including because one or more of the assumptions underlying our cash burn or runway expectations may not be realized); the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all; the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, product development activities and regulatory approval requirements (including the risk that data from our ongoing and planned clinical research programs in may not support registration or further development of its product candidates due to safety or efficacy concerns or any other reasons); the inherent risks and uncertainties associated with target discovery and validation, and drug discovery and development activities; the risk that the initial and topline data from our trials and studies, including, but not limited to, the ATALANTA-1 and EUPLAGIA-1 studies, may not be reflective of the final data; risks related to our reliance on collaborations with third parties (including but not limited to, Gilead and Lonza); the risk that estimates regarding the commercial potential of our product candidates will be incorrect; and the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (“SEC”) including in our most recent annual report on Form 20-F filed with the SEC, and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the results of our results, performance, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation to update any such statements herein to reflect any change in our expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

Our drug candidates mentioned in this presentation are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority. Under no circumstances may any copy of this presentation, if obtained, be retained, copied or transmitted.

Key Milestones in 2024



Significant progress made with flagship CD19 CAR-T, GLPG5101 in R/R NHL

- Received FDA clearance for IND application for Phase 1/2 ATALANTA-1 study
- Announced encouraging new results from ongoing Phase 1/2 study at EHA and ASH



Multiple partnerships and strategic collaborations

- Lonza
- Thermo Fisher Scientific
- Blood Centers of America
- Adaptimmune for TCR T-cell therapy



Completed transaction to transfer Jyseleca® business to Alfasigma

- Achieved annualized savings of approximately €200M
- Eligible for mid-single to mid-double digit royalties on European sales from Alfasigma

Plan to Separate Into Two Publicly Traded Entities

Focus on Accelerating Value Creation

Separating into Two Publicly Traded Entities

Exciting opportunity to benefit all of Galapagos' shareholders:

- **SpinCo** will invest to **build a pipeline of innovative medicines** with demonstrated **clinical proof of concept** through transformational transactions (acquisitions, licensing) in oncology, immunology, and virology
- **Galapagos** will focus on accelerating global oncology leadership in transformational cell therapies, with **full global development and commercialization rights** to its R&D pipeline
- SpinCo will assume the **OLCA*** and will continue to collaborate with Gilead
- Galapagos will **seek partners** for its small molecule programs, including for its TYK2 inhibitor, and **discontinue its future small molecule research**

Each company will have the flexibility to allocate resources, pursue tailored strategies, and maximize opportunities for growth and impact in their respective areas to enhance shareholder value





The New Galapagos Opportunity


Unlocking the Potential of Galapagos

Strong fundamentals in place to advance our innovative biotechnology company



Strategic Flexibility

Ability to partner as of separation on pipeline and platform



Deliver on clinical progress

Accelerate and expand clinical trials in US & EU. Aim to start registrational studies in 2026



Build global network and leverage platform with partners

Lonza, Thermo Fisher, Landmark Bio, Blood Centers of America and Catalent



Progress early-stage pipeline

Next-generation, multi-targeting, armored cell therapies for hematological and solid tumors



Strong capabilities with world class talent

Strengthening our US capabilities to prepare for launch of our first CAR-T

Decentralized Manufacturing is Core to Our Strategy

Fresh cells produced by **decentralized** manufacturing have potential to enhance the therapeutic profile of cell therapy assets

Overcomes limitations associated with current cell therapies, including **logistical** and **cost** burdens

To demonstrate **platform potential**, Galapagos focuses initial clinical application on assets with validated biology



Our process is designed for fresh, stem-like, early memory cell therapy



Designed for *in vivo* expansion and persistence of highly potent cells, that are less **exhausted**, less **toxic** and **persist** longer

Robust Cell Therapy Pipeline

Advancing multiple potential best-in-class programs

	PRODUCT CANDIDATE	TARGET	STUDY	DRUG CLASS	INDICATION	DISCOVERY	IND/CTA-ENABLING	PHASE 1	PHASE 2
HEMATOLOGICAL TUMORS	GLPG5101 ¹	CD19	ATALANTA-1	CAR T-cell therapy	R/R non-Hodgkin lymphoma	FL or MZL			
						MCL			
						PCNSL			
						DCBCL			
						High risk DLBCL			
						DLBCL-RT			
						BL			
						R/R chronic lymphocytic leukemia ¹			
GLPG5201 ²	CD19	EUPLAGIA-1	CAR T-cell therapy	R/R chronic lymphocytic leukemia	CLL				
					RT				
GLPG5301	BCMA	PAPILIO-1	CAR T-cell therapy	R/R multiple myeloma	MM				
Armored bi-specific	Undisclosed		CAR T-cell therapy	Hematological tumors					
Next-gen assets	Multiple		CAR T-cell therapy	Hematological tumors					
SOLID TUMORS	Uza-cel ³	MAGE-A4		TCR T-cell therapy	Head & neck cancer				
	Next-gen assets	Multiple		Cell therapy	Solid tumors				

¹We are expanding the development of GLPG5101, our most advanced asset by extending its reach into additional aggressive B-cell malignancies, including Richter transformation of CLL, and are taking action to expand into double-refractory CLL pending regulatory approval.


²We are deprioritizing activities related to GLPG5201, our second CD19 CAR-T candidate, pending the advancement of GLPG5101 in RT of CLL and R/R CLL.

³Subject to opt-in under collaboration and exclusive license agreement with Adaptimmune for uza-cel (ADP-A2M4CD8) signed and announced on 30 May 2024.

BL, Burkitt lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; High-risk DLBCL with International Prognostic Index 3-5 or double/triple-hit lymphoma, primary refractory disease, defined as subjects failing to achieve a complete response to first-line anti-CD20 and anthracycline-based chemoimmunotherapy after ≥2 cycles at the interim disease assessment; MCL, mantle cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; Next-gen, next-generation; PCNSL, primary central nervous system lymphoma; R/R relapsed/refractory; RT, Richter transformation.

ATLANTA-1^a: Efficacy from Pooled Ph1/2 Results

High OR and CR rates were observed (best response at any time after infusion)^b




^aCTIS: 2022-502661-23-00; NCT06561425. ^bTwo patients who received cryopreserved product were not included in the efficacy analyses; both patients were in CR at data cutoff. ^bThree patients with FL were not included in the Phase 2 response outputs as the first response assessment data were not available at data cutoff. **Data cutoff: 25 April 2024.**

CR, complete response; CRR, complete response rate; DL, dose level; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; OR, objective response; ORR, objective response rate; PR, partial response. Presented at the 66th ASH Annual Congress: December 7-10, 2024; San Diego, CA, USA.

ATLANTA-1 Efficacy: Response Over Time

Durable responses were observed



Plot shows duration of follow-up for each patient until last response assessment. ^aOne patient died before first response assessment and is not included in median follow-up data.



^bThree patients with FL were not included in the Phase 2 response outputs as the first response assessment data were not available at data cutoff. **Data cutoff: 25 April 2024.**

CAR, chimeric antigen receptor; CR, complete response; DL, dose level; DLBCL, diffuse large B-cell lymphoma; EOS, end of study; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; PD, progressive disease; PR, partial response; SD, stable disease. Presented at the 66th ASH Annual Congress: December 7-10, 2024; San Diego, CA, USA.

Duration of Response in Patients in CR by MRD Status

All patients who were MRD negative at CR remained in CR at data cutoff (ATALANTA-1)

Longer PFS was observed in patients who were MRD negative at CR
MRD negativity occurred in 12/15 (80%) evaluable patients who achieved CR



Plot on right shows the duration of follow-up for each patient until the last response assessment. MRD in plasma was evaluated after patients reached CR using the Adaptive clonoSEQ assay. Suboptimal plasma volumes were analyzed for a few samples, which may impact clinical sensitivity of the results. ^aIn MRD-negative patients: 1 censoring event at Day 171 and 2 censoring events at Day 183.

Data cutoff: 25 April 2024. CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MRD, minimal residual disease; MZL, marginal zone lymphoma; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. Presented at the 66th ASH Annual Congress: December 7-10, 2024; San Diego, CA, USA.

GLPG5101 ATALANTA-1 Summary

In the ongoing ATALANTA-1 study, **100% of patients with R/R MCL, 95% of patients with R/R FL/MZL, and 54% of patients with R/R DLBCL (71% for those receiving DL2) achieved a CR**

Of evaluable patients achieving CR, **80% were MRD negative and remained in CR at data cutoff**

GLPG5101 demonstrates a **manageable safety profile**

- with only 1 case of Grade 3 CRS and 1 case of Grade 3 ICANS reported in a cohort of 45 patients
-

GLPG5101, a **fresh, stem-like, early memory CD19 CAR T-cell therapy**

GLPG3667: a Selective TYK2 inhibitor


In Phase 3-enabling trials to treat SLE and DM; Attractive partnership opportunity



Mediator of
Type I IFN &
IL-12/23 signaling



Demonstrated
safety/tolerability
and clinical activity
in a PsO P1b study



Potential in several
autoimmune
indications

**Screening for the SLE study was completed in January 2025, ahead of schedule.
Topline results for the entire GLPG3667 program are anticipated in the first half of 2026.**

Opportunity to Build Value by Partnering Small Molecule Portfolio

Leveraging 25+ years of R&D expertise in oncology and immunology

Oncology

- >5 programs across cancer types identified
- Deliver precision medicines

Immunology

- >5 programs across immunology indications identified
- Potential best-in-class small molecule candidate progressed into IND enabling studies

PRODUCT CANDIDATE	TARGET	STUDY	DRUG CLASS	INDICATION	DISCOVERY	IND-ENABLING	PHASE 1	PHASE 2
pBIC candidate	Undisclosed		Small molecule	Inflammatory bowel disease				
pBIC assets	Multiple		Small molecule	Inflammation/auto-immune disorders				
pBIC assets	Multiple		Small molecule	Solid tumors				

Near-Term Value Creating Catalysts

Driving Galapagos Forward

Enroll patients in U.S. and Europe in Phase 2 ATALANTA-1 study in **multiple indications**

Aim to **start registrational studies** with GLPG5101 in 2026

Expanding DMU network in U.S. and Europe

Complete Phase 3-enabling TYK2i studies in SLE and DM, while seeking partnerships

Advance early-stage next generation cell therapies in hematological and solid tumors, including uza-cel


SpinCo Value Proposition



Market Environment Creates Opportunity



Tightened Financing Environment



Breakthrough Scientific and Clinical Advances



Significant Opportunity to Build Value

Next Steps and Anticipated Milestones

SpinCo

Prepare for spin-off and listing of **SpinCo** on **Euronext** and **Nasdaq** by **mid-2025**^{1,2}

Seasoned executive team and **independent non-executive directors** with proven track record in biotech company-building and strategic transaction execution, to be **identified in coming months**

Prospectus to be made publicly available at least a month prior to the spin-off

All Galapagos shareholders to receive SpinCo shares on a **pro rata basis**, proportional to their ownership of Galapagos shares³



Full Year 2024

Financial Results

Full Year 2024 Key Figures

(€ millions)

	DECEMBER 31, 2024	DECEMBER 31, 2023	% CHANGE
Supply revenues	34.8	-	
Collaboration revenues	240.8	239.7	
Total revenues	275.6	239.7	+15%
Cost of sales	(34.8)	-	
R&D expenses	(335.4)	(241.3)	+39%
G&A and S&M expenses	(134.4)	(134.0)	
Other operating income	40.8	47.3	-14%
Operating loss	(188.3)	(88.3)	
Net financial result	185.3	93.9	
Income taxes	1.8	(9.6)	
Net loss from continuing operations	(1.3)	(4.0)	
Net profit from discontinuing operations, net of tax	75.4	215.7	
Net profit of the year	74.1	221.7	

Revenues driven by

- €230.2M revenue recognition for discovery platform


Investing in oncology TA

- Increase in R&D (+39%) YoY mainly driven by expansion in oncology in CAR-T

Net profit driven by

- €185.3M fair value adjustments, currency exchange results and interest income
- Net profit from discontinuing operations, including €52.5M gain on the sale of the Jyseleca® business to Alfasigma

Balance Sheet & Operational Changes



¹Including €79M for the Adaptimmune collaboration (May 30, 2024)

²As of December 31, 2024

³Excluding restructuring costs

⁴With the assumption that separation occurs mid year

Guidance based on current Galapagos management estimates.

Galapagos

Unlocking value

SpinCo

Full focus to **accelerate our flagship CD19 program** with the decentralized manufacturing model

Develop next-gen cell therapy programs in hematological and solid tumors

Develop a worldwide DMU network with decentralized cell therapy

Autonomy to partner our differentiated cell therapy pipeline & network

Significant restructuring to realign the company's strategy and reduce cash burn

Full focus on **building a pipeline of innovative medicines** through transformational transactions

Well capitalized with ~€2.45B to pursue high-quality assets, fund development, portfolio investment

Ability to **leverage Gilead's strong expertise, and late-stage and commercial capabilities**, in key therapeutic areas

SpinCo Board to have a **majority independent directors** and **experienced executive leadership team**

Gilead has committed to negotiating **in good faith amendments to the OLCA** on a transaction-by-transaction basis to achieve **positive value** for SpinCo and all of its shareholders

Plan to Separate Into Two Publicly Traded Entities

Focus on Accelerating Value Creation

Q&A